Place · Level 3 · Vitamin
Vitamin K1 (Phylloquinone)
绿叶里的凝血因子激活剂 · γ-羧化让 II/VII/IX/X 抓住钙 · 新生儿出血预防 · 华法林为何要稳
Story path
Chapter 1
K1 lives in leaves
K1 lives in leaves
Vitamin K1 (phylloquinone) is part of the chloroplast machinery in plant leaves, where it participates in photosynthetic electron transport. The greener the leaf, the higher the K1:
Kale, cooked, 100 g: ~820 µg — the leaderSpinach, cooked, 100 g: ~540 µgBroccoli, cooked, 100 g: ~140 µgLettuce (large leaf), 100 g: ~50-100 µgSoybean / canola oil: moderate amounts — one of the main K1 sources in Western diets
AI (Adequate Intake, IOM) targets: 120 µg/day men, 90 µg/day women — a single cup of cooked spinach exceeds the daily target.
K1 vs K2 division of labor: K1 mainly serves the liver, activating clotting factors II / VII / IX / X; K2 takes the osteocalcin + MGP path (see the Atlas vitamin-k2 story). Structurally the head is the same (naphthoquinone core); the difference is in the tail — K1 has a single isoprenoid side chain, K2 has multiple (MK-4 to MK-13). The body can interconvert small amounts of K1 → MK-4, but not enough to cover the full range of K2 functions.
'I eat greens daily, I shouldn't be K1-deficient' is essentially correct — this is one of nutrition teaching's rare 'if the diet structure is normal, you're covered' cases. Real K1 deficiency occurs in: long-term TPN (parenteral nutrition), severe fat malabsorption, long-term broad-spectrum antibiotic use, anticonvulsant use, and newborns (see later scene).
Kale, cooked, 100 g: ~820 µg — the leaderSpinach, cooked, 100 g: ~540 µgBroccoli, cooked, 100 g: ~140 µgLettuce (large leaf), 100 g: ~50-100 µgSoybean / canola oil: moderate amounts — one of the main K1 sources in Western diets
AI (Adequate Intake, IOM) targets: 120 µg/day men, 90 µg/day women — a single cup of cooked spinach exceeds the daily target.
K1 vs K2 division of labor: K1 mainly serves the liver, activating clotting factors II / VII / IX / X; K2 takes the osteocalcin + MGP path (see the Atlas vitamin-k2 story). Structurally the head is the same (naphthoquinone core); the difference is in the tail — K1 has a single isoprenoid side chain, K2 has multiple (MK-4 to MK-13). The body can interconvert small amounts of K1 → MK-4, but not enough to cover the full range of K2 functions.
'I eat greens daily, I shouldn't be K1-deficient' is essentially correct — this is one of nutrition teaching's rare 'if the diet structure is normal, you're covered' cases. Real K1 deficiency occurs in: long-term TPN (parenteral nutrition), severe fat malabsorption, long-term broad-spectrum antibiotic use, anticonvulsant use, and newborns (see later scene).
Greens-thicken-blood myth
'Greens are high in vitamin K, eating more thickens the blood and raises clot risk' — for almost everyone this is completely wrong.Comparing the data point by point: in healthy adults at K1 intakes between 50 and 800 µg/day, prothrombin time (PT / INR) barely moves; the body only uses what it needs to γ-carboxylate clotting factors, and excess K1 is metabolized in the liver and excreted; epidemiology shows no dose-response relationship between 'high K1' and clotting events; observational data actually point the opposite way — people who eat more greens have fewer cardiovascular events (composite of K2, folate, potassium, fiber, and nitrates).
The only people who really need stable K1 intake are patients on warfarin. But the answer is not 'avoid greens', it's 'eat about the same amount every day' — the physician sets the warfarin dose against that baseline (see the anticoagulants scene).
Patients on DOACs (dabigatran / rivaroxaban / apixaban / edoxaban) bypass the K cycle entirely — eat all the greens you want.
So for ordinary people, more greens carry no clotting risk. The claim's origin traces to 1990s 'spinach + warfarin' clinical cases that were incorrectly generalized to healthy populations — the vascular protection of greens far outweighs any imagined 'thicker blood' risk.
Chapter 2
Gut absorption · fat-soluble
Gut absorption · fat-soluble
K1 is fat-soluble, in the same group as A / D / E, and needs to be eaten with fat for proper absorption.
Absorption path (in order):
1. Duodenum / upper jejunum: dietary K1 is embedded in chloroplast thylakoid membranes; bile acids and pancreatic lipase dissolve it out, emulsifying into mixed micelles.
2. Enterocyte: uptake via the NPC1L1 receptor plus passive diffusion.
3. Packaged into chylomicrons: into lymph, then into venous circulation, finally to the liver.
4. Liver: K1 is mostly taken up by hepatocytes; storage is minimal (only 1-2 days of supply), so daily intake is required.
Absorption efficiency ~10-15%, lower than D or E. Key modifiers:
Raw vs cooked: cooked greens absorb 2-3× better than raw — heat opens cell walls and oil helps dissolveAdding oil: salad drizzled with olive oil + avocado can multiply K1 absorption several-foldWhole leaves vs juice: green juice has high free K1 but lacks the fat carrier, so actual absorption is worse than 'vegetables + oil'
Poor-absorption populations:
Cystic fibrosis (CF) or chronic pancreatitis: pancreatic lipase insufficiency → fat-soluble vitamin K deficiencyBile acid deficiency (biliary obstruction / severe liver disease): can't form micellesCrohn's, short bowel syndrome, severe gluten intolerance: distal small bowel or colon dysfunctionOrlistat (weight-loss drug): blocking fat absorption blocks KBile-acid sequestrant resins (cholestyramine): same blockageLong-term broad-spectrum antibiotics: gut bacterial long-chain MK synthesis falls, affecting K2 more than K1 but compounding
Practical: healthy adults are fine with greens + fat + normal diet; people with absorption disorders can work with their dietitian or GI team on water-solubilized K1 (Konakion MM, micellar form) or injectable forms; infants in the first few months have immature GI tracts and very low K1 in breast milk, so an IM shot at birth is standard (see next scene).
Absorption path (in order):
1. Duodenum / upper jejunum: dietary K1 is embedded in chloroplast thylakoid membranes; bile acids and pancreatic lipase dissolve it out, emulsifying into mixed micelles.
2. Enterocyte: uptake via the NPC1L1 receptor plus passive diffusion.
3. Packaged into chylomicrons: into lymph, then into venous circulation, finally to the liver.
4. Liver: K1 is mostly taken up by hepatocytes; storage is minimal (only 1-2 days of supply), so daily intake is required.
Absorption efficiency ~10-15%, lower than D or E. Key modifiers:
Raw vs cooked: cooked greens absorb 2-3× better than raw — heat opens cell walls and oil helps dissolveAdding oil: salad drizzled with olive oil + avocado can multiply K1 absorption several-foldWhole leaves vs juice: green juice has high free K1 but lacks the fat carrier, so actual absorption is worse than 'vegetables + oil'
Poor-absorption populations:
Cystic fibrosis (CF) or chronic pancreatitis: pancreatic lipase insufficiency → fat-soluble vitamin K deficiencyBile acid deficiency (biliary obstruction / severe liver disease): can't form micellesCrohn's, short bowel syndrome, severe gluten intolerance: distal small bowel or colon dysfunctionOrlistat (weight-loss drug): blocking fat absorption blocks KBile-acid sequestrant resins (cholestyramine): same blockageLong-term broad-spectrum antibiotics: gut bacterial long-chain MK synthesis falls, affecting K2 more than K1 but compounding
Practical: healthy adults are fine with greens + fat + normal diet; people with absorption disorders can work with their dietitian or GI team on water-solubilized K1 (Konakion MM, micellar form) or injectable forms; infants in the first few months have immature GI tracts and very low K1 in breast milk, so an IM shot at birth is standard (see next scene).
Chapter 3
γ-carboxylation cycle
γ-carboxylation cycle
K1's job is to give a specific group of proteins 'calcium-gripping ability' — via γ-carboxylation, converting Glu (glutamate) residues into Gla (γ-carboxyglutamate). The reaction takes place in the hepatic endoplasmic reticulum; the main enzyme is GGCX (γ-glutamyl carboxylase), with reduced K1 (hydroquinone, KH₂) as cofactor.
The 5-step reaction cycle:
1. KH₂ + O₂ → forms a strong base intermediate that abstracts a proton from the Glu side chain
2. Naked Glu residue + CO₂ → forms a new C-C bond → Gla (one extra carboxyl group)
3. KH₂ is oxidized in this step to K1-2,3-epoxide (K1-O), now inactive
4. VKORC1 (vitamin K epoxide reductase complex 1) reduces K1-O back to KH₂, ready for the next cycle
5. The whole cycle closes and the cofactor is reused: one K1 molecule can activate tens to hundreds of clotting factor proteins
Why Gla matters: Gla's two carboxyls carry negative charges, acting like tiny calcium clamps that grip Ca²⁺ electrostatically; clotting factors with Gla can then bind Ca²⁺ on phospholipid membrane surfaces and assemble into clotting complexes. Without Gla, factors float in blood completely non-functional.
This cycle is warfarin's target: warfarin precisely inhibits VKORC1 → K1-O can't be reduced back to KH₂ → GGCX stalls → newly synthesized clotting factors remain in the Glu form (PIVKA, protein induced by vitamin K absence) → clotting time prolonged (INR rises). Conversely, eating K1 directly supplies KH₂, partially bypassing the VKORC1 step and undoing warfarin's effect — this is why 'warfarin + suddenly eating lots of spinach = INR crashes'.
This section's L4 micro-animation steps through GGCX catalysis, VKORC1 recycling of K1-O, and the precise step where warfarin jams — one of the Atlas's most classic 'one molecular switch controls whole-body clotting' cases.
The 5-step reaction cycle:
1. KH₂ + O₂ → forms a strong base intermediate that abstracts a proton from the Glu side chain
2. Naked Glu residue + CO₂ → forms a new C-C bond → Gla (one extra carboxyl group)
3. KH₂ is oxidized in this step to K1-2,3-epoxide (K1-O), now inactive
4. VKORC1 (vitamin K epoxide reductase complex 1) reduces K1-O back to KH₂, ready for the next cycle
5. The whole cycle closes and the cofactor is reused: one K1 molecule can activate tens to hundreds of clotting factor proteins
Why Gla matters: Gla's two carboxyls carry negative charges, acting like tiny calcium clamps that grip Ca²⁺ electrostatically; clotting factors with Gla can then bind Ca²⁺ on phospholipid membrane surfaces and assemble into clotting complexes. Without Gla, factors float in blood completely non-functional.
This cycle is warfarin's target: warfarin precisely inhibits VKORC1 → K1-O can't be reduced back to KH₂ → GGCX stalls → newly synthesized clotting factors remain in the Glu form (PIVKA, protein induced by vitamin K absence) → clotting time prolonged (INR rises). Conversely, eating K1 directly supplies KH₂, partially bypassing the VKORC1 step and undoing warfarin's effect — this is why 'warfarin + suddenly eating lots of spinach = INR crashes'.
This section's L4 micro-animation steps through GGCX catalysis, VKORC1 recycling of K1-O, and the precise step where warfarin jams — one of the Atlas's most classic 'one molecular switch controls whole-body clotting' cases.
Chapter 4
Factors II/VII/IX/X · cascade
Factors II/VII/IX/X · cascade
K1-activated clotting factors total 7 (in hepatic synthesis order):
Factor II (prothrombin): becomes thrombin (IIa) at the end of the cascadeFactor VII: starts the extrinsic pathway; shortest half-life (~4-6 h), so warfarin disables this one first — early INR rise is driven mainly by VII fallingFactor IX: intrinsic pathway; deficiency is hemophilia BFactor X: common pathway, activates thrombinProtein C / S: anticoagulant brake (opposing clotting); on early warfarin Protein C falls faster than the procoagulants, producing a transient hypercoagulable state — this is the chemical basis of the rare 'warfarin skin necrosis' and the rationale for heparin bridgingProtein Z: clotting adjunct
Extrinsic pathway (the main in-vivo initiation): vessel injury → tissue factor (TF) exposed → TF + factor VIIa + Ca²⁺ + phospholipid membrane → activates factor X → Xa + Va + Ca²⁺ + phospholipid → prothrombin (II) → thrombin (IIa) → fibrinogen → fibrin mesh → clot. Every step requires Gla residues anchoring to Ca²⁺ on phospholipid membranes — this is K1's core contribution.
Common clinical lab indicators:
PT (prothrombin time): covers extrinsic + common pathways, sensitive to factors VII / X / II — the primary warfarin monitoring markerINR: PT standardized form, comparable across labsaPTT: intrinsic + common pathways, sensitive to factors IX / VIII / XI — mainly used for heparin monitoringPIVKA-II: under-carboxylated prothrombin; rises in K1 deficiency or warfarin excess; also a hepatocellular carcinoma marker
Clinical signs of severe K1 deficiency (rare): bleeding gums, epistaxis, menorrhagia, easy bruising; PT / INR markedly prolonged, aPTT possibly prolonged (factor IX affected); severe cases can present with GI hemorrhage or intracranial bleeding. Treatment is usually K1 5-10 mg IV or IM; severe cases add PCC (prothrombin complex concentrate) plus transfusion.
Factor II (prothrombin): becomes thrombin (IIa) at the end of the cascadeFactor VII: starts the extrinsic pathway; shortest half-life (~4-6 h), so warfarin disables this one first — early INR rise is driven mainly by VII fallingFactor IX: intrinsic pathway; deficiency is hemophilia BFactor X: common pathway, activates thrombinProtein C / S: anticoagulant brake (opposing clotting); on early warfarin Protein C falls faster than the procoagulants, producing a transient hypercoagulable state — this is the chemical basis of the rare 'warfarin skin necrosis' and the rationale for heparin bridgingProtein Z: clotting adjunct
Extrinsic pathway (the main in-vivo initiation): vessel injury → tissue factor (TF) exposed → TF + factor VIIa + Ca²⁺ + phospholipid membrane → activates factor X → Xa + Va + Ca²⁺ + phospholipid → prothrombin (II) → thrombin (IIa) → fibrinogen → fibrin mesh → clot. Every step requires Gla residues anchoring to Ca²⁺ on phospholipid membranes — this is K1's core contribution.
Common clinical lab indicators:
PT (prothrombin time): covers extrinsic + common pathways, sensitive to factors VII / X / II — the primary warfarin monitoring markerINR: PT standardized form, comparable across labsaPTT: intrinsic + common pathways, sensitive to factors IX / VIII / XI — mainly used for heparin monitoringPIVKA-II: under-carboxylated prothrombin; rises in K1 deficiency or warfarin excess; also a hepatocellular carcinoma marker
Clinical signs of severe K1 deficiency (rare): bleeding gums, epistaxis, menorrhagia, easy bruising; PT / INR markedly prolonged, aPTT possibly prolonged (factor IX affected); severe cases can present with GI hemorrhage or intracranial bleeding. Treatment is usually K1 5-10 mg IV or IM; severe cases add PCC (prothrombin complex concentrate) plus transfusion.
Chapter 5
Newborn K1 shot · VKDB
Newborn K1 shot · VKDB
1 mg IM K1 within 6 hours of birth is one of global public health's most universal 'single-shot vitamin interventions' — recommended by the AAP, WHO, and CDC.
Why infants are K-deficient high risk: the placenta is poorly permeable to K1, so K1 stores at birth are nearly zero; the newborn gut is sterile, with no endogenous K2 synthesis; breast milk has very low K1 (~1-4 µg/L; formula is fortified to ~50 µg/L); the liver is still immature, so clotting factor synthesis is naturally low.
Without supplementation — VKDB (Vitamin K Deficiency Bleeding) three types:
Late VKDB occurs almost exclusively in 'exclusively breast-fed + un-supplemented' infants — a historical lesson: pre-1961, ICH was a common neonatal cause of death; after 1961 standardization of 1 mg IM K1, VKDB incidence dropped from 0.25-1.7% to near zero; in 2000s US, increased parental refusal of the shot brought multiple ICH cases back, and the AAP 2022 strengthened the recommendation.
'K1 injection causes cancer' rumor — origin and rebuttal: the 1992 Golding single-center study incorrectly linked IM K1 to childhood leukemia; 20+ subsequent large cohorts have all refuted this (Roman 2002, McKinney 2003, Parker 2009, Fear 2003); modern consensus is that K1 injection is safe, necessary, and not carcinogenic.
Oral alternative protocols (Netherlands, Denmark, parts of Germany): 2 mg PO × 3 doses (birth / 1 wk / 4 wk) or longer; efficacy approaches injection but requires strict follow-up and has missed-dose risk; biliary atresia infants (occult absorption defect) can still develop late VKDB — which is exactly why the IM shot remains the safety net.
The Day-1 K1 shot is one of the cheapest and most effective public-health interventions in 60 years of neonatal medicine.
Why infants are K-deficient high risk: the placenta is poorly permeable to K1, so K1 stores at birth are nearly zero; the newborn gut is sterile, with no endogenous K2 synthesis; breast milk has very low K1 (~1-4 µg/L; formula is fortified to ~50 µg/L); the liver is still immature, so clotting factor synthesis is naturally low.
Without supplementation — VKDB (Vitamin K Deficiency Bleeding) three types:
| Type | Timing | Location | Death / disability |
|---|---|---|---|
| Early | < 24 h | Visceral / cranial / scalp | Maternal anticoagulant or anticonvulsant related, rare |
| Classic | 1-7 days | GI / umbilical / nasal / skin | Mostly self-limited, mortality 5-15% |
| Late | 2 wk - 6 mo | ~50% present as intracranial hemorrhage (ICH) | Mortality ~20%, ~40% of survivors severely disabled |
Late VKDB occurs almost exclusively in 'exclusively breast-fed + un-supplemented' infants — a historical lesson: pre-1961, ICH was a common neonatal cause of death; after 1961 standardization of 1 mg IM K1, VKDB incidence dropped from 0.25-1.7% to near zero; in 2000s US, increased parental refusal of the shot brought multiple ICH cases back, and the AAP 2022 strengthened the recommendation.
'K1 injection causes cancer' rumor — origin and rebuttal: the 1992 Golding single-center study incorrectly linked IM K1 to childhood leukemia; 20+ subsequent large cohorts have all refuted this (Roman 2002, McKinney 2003, Parker 2009, Fear 2003); modern consensus is that K1 injection is safe, necessary, and not carcinogenic.
Oral alternative protocols (Netherlands, Denmark, parts of Germany): 2 mg PO × 3 doses (birth / 1 wk / 4 wk) or longer; efficacy approaches injection but requires strict follow-up and has missed-dose risk; biliary atresia infants (occult absorption defect) can still develop late VKDB — which is exactly why the IM shot remains the safety net.
The Day-1 K1 shot is one of the cheapest and most effective public-health interventions in 60 years of neonatal medicine.
Chapter 6
Warfarin vs DOAC
Warfarin vs DOAC
Anticoagulant choice has gone through a paradigm shift in the past 15 years — most patients have moved from warfarin to DOACs (Direct Oral Anticoagulants).
Mechanism comparison:
Warfarin: inhibits VKORC1 → clotting factors II/VII/IX/X all inactivated (running through the K1 cycle); slow onset (3-5 days), slow offset (5-7 days)Dabigatran (Pradaxa): direct thrombin (IIa) inhibitor, doesn't touch KRivaroxaban (Xarelto) / apixaban (Eliquis) / edoxaban (Lixiana): direct factor Xa inhibitors, don't touch KDOAC shared features: onset 2-4 h, offset 1-2 days, no routine INR monitoring, dietary K doesn't affect drug action
Pivotal RCT — ARISTOTLE (Granger 2011, NEJM): 18,201 atrial fibrillation patients randomized to apixaban vs warfarin; apixaban reduced stroke / systemic embolism by 21%, major bleeding by 31%, all-cause mortality by 11%. RE-LY (dabigatran), ROCKET-AF (rivaroxaban), and ENGAGE AF-TIMI 48 (edoxaban) gave directionally consistent results. So modern AF guidelines (AHA / ESC) list DOACs as first-line.
Scenarios where warfarin remains first choice (DOACs unsuitable or data insufficient):
Mechanical valves (RE-ALIGN negative — DOACs are contraindicated here)High-risk antiphospholipid syndrome (APS)Severe renal failure (eGFR < 15-30 — DOACs excluded or need dose adjustment)Pregnancy (warfarin is teratogenic but DOAC data are even thinner — LMWH is usually used)Cost: warfarin ¥30-80/month vs DOAC ¥500-2000/month
Warfarin + K1 dietary practical (if you're on warfarin): don't avoid all greens (that's the old wrong advice); eat about the same amount of greens daily (e.g., 1 cup cooked spinach/day) and let the physician dose warfarin against that baseline; suddenly eating 5 cups of spinach drops INR and raises clot risk; suddenly cutting greens raises INR and bleeding risk; the principle is 'stable + monitor + adjust dose', not 'avoid'. INR targets: AF / DVT / PE 2.0-3.0, mechanical valves 2.5-3.5. INR > 5 without bleeding: usually skip a dose and recheck; INR > 10 without bleeding: K1 2.5-5 mg PO; major bleeding: K1 10 mg IV + PCC + transfusion.
DOAC users have complete dietary freedom on K1 foods and K2 supplements — this is the real quality-of-life dividend of DOACs.
'Anticoagulant = warfarin' is a 30-year-old mental model. Most AF / DVT / PE patients today are recommended DOACs; warfarin remains the gold standard for mechanical valves, APS, and severe renal failure — so K1 knowledge still matters.
Mechanism comparison:
Warfarin: inhibits VKORC1 → clotting factors II/VII/IX/X all inactivated (running through the K1 cycle); slow onset (3-5 days), slow offset (5-7 days)Dabigatran (Pradaxa): direct thrombin (IIa) inhibitor, doesn't touch KRivaroxaban (Xarelto) / apixaban (Eliquis) / edoxaban (Lixiana): direct factor Xa inhibitors, don't touch KDOAC shared features: onset 2-4 h, offset 1-2 days, no routine INR monitoring, dietary K doesn't affect drug action
Pivotal RCT — ARISTOTLE (Granger 2011, NEJM): 18,201 atrial fibrillation patients randomized to apixaban vs warfarin; apixaban reduced stroke / systemic embolism by 21%, major bleeding by 31%, all-cause mortality by 11%. RE-LY (dabigatran), ROCKET-AF (rivaroxaban), and ENGAGE AF-TIMI 48 (edoxaban) gave directionally consistent results. So modern AF guidelines (AHA / ESC) list DOACs as first-line.
Scenarios where warfarin remains first choice (DOACs unsuitable or data insufficient):
Mechanical valves (RE-ALIGN negative — DOACs are contraindicated here)High-risk antiphospholipid syndrome (APS)Severe renal failure (eGFR < 15-30 — DOACs excluded or need dose adjustment)Pregnancy (warfarin is teratogenic but DOAC data are even thinner — LMWH is usually used)Cost: warfarin ¥30-80/month vs DOAC ¥500-2000/month
Warfarin + K1 dietary practical (if you're on warfarin): don't avoid all greens (that's the old wrong advice); eat about the same amount of greens daily (e.g., 1 cup cooked spinach/day) and let the physician dose warfarin against that baseline; suddenly eating 5 cups of spinach drops INR and raises clot risk; suddenly cutting greens raises INR and bleeding risk; the principle is 'stable + monitor + adjust dose', not 'avoid'. INR targets: AF / DVT / PE 2.0-3.0, mechanical valves 2.5-3.5. INR > 5 without bleeding: usually skip a dose and recheck; INR > 10 without bleeding: K1 2.5-5 mg PO; major bleeding: K1 10 mg IV + PCC + transfusion.
DOAC users have complete dietary freedom on K1 foods and K2 supplements — this is the real quality-of-life dividend of DOACs.
'Anticoagulant = warfarin' is a 30-year-old mental model. Most AF / DVT / PE patients today are recommended DOACs; warfarin remains the gold standard for mechanical valves, APS, and severe renal failure — so K1 knowledge still matters.
Anticoagulant × vitamin K cheat sheet
You or a family member on anticoagulation? One table clarifies each anticoagulant's relationship to vitamin K:| Drug | Mechanism | Monitoring | K1 diet | K2 supplement |
|---|---|---|---|---|
| Warfarin | Blocks VKORC1 | INR every 1-4 weeks | Stable daily | Must ask MD |
| Dabigatran (Pradaxa) | Inhibits IIa | None routine | Free | Free |
| Apixaban (Eliquis) | Inhibits Xa | None routine | Free | Free |
| Rivaroxaban (Xarelto) | Inhibits Xa | None routine | Free | Free |
| Edoxaban (Lixiana) | Inhibits Xa | None routine | Free | Free |
| LMWH (Clexane) | Inhibits Xa / IIa | Anti-Xa (occasionally) | Free | Free |
| Aspirin | Inhibits platelets | None | Free | Free |
Common Q&A:
'I'm on aspirin, can I eat lots of spinach?' Yes — aspirin doesn't run through the K cycle.'I just started warfarin, do I have to give up greens?' No — eat about the same amount daily; tell your physician your normal greens portion and they dose against it.'I switched to apixaban; can I have the natto I avoided on warfarin?' Yes — DOACs don't care about K.'Elderly relative on warfarin, winter cuts vegetable intake, INR drifting up — what to do?' Real scenario; increase INR check frequency, may need a dose reduction.'Will K2 (MK-7) supplements antagonize warfarin?' Yes. K2 is also a KH₂ donor; any K form antagonizes warfarin — disclose to your physician before starting K2 and adjust dose accordingly.
Links to other Atlas stories:
vitamin-k2 L3 + L4 (osteocalcin + MGP)calcium + bone L3 (D / K2 / Ca triad)vitamin-d L3 (D-K-Ca synergy)cardiovascular / atherosclerosis L4 (vascular calcification)alcohol-metabolism / liver-disease (hepatic clotting factor synthesis)
One sentence: K1 is the clotting key in green leaves — food sources are abundant, and healthy people don't need a dedicated supplement; the practical question isn't 'enough or not', it's 'how to coordinate with medications'.